- Home
- Publications
- Publication Search
- Publication Details
Title
Allogeneic Stem Cell Transplantation in Multiple Myeloma
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 1, Pages 55
Publisher
MDPI AG
Online
2021-12-23
DOI
10.3390/cancers14010055
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high‐risk myeloma patients – a single centre experience
- (2021) Amanda Jurgensen‐Rauch et al. BRITISH JOURNAL OF HAEMATOLOGY
- Long-term outcome after allogeneic stem cell transplantation in multiple myeloma
- (2021) Sini Luoma et al. ANNALS OF HEMATOLOGY
- European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
- (2021) Benedetto Bruno et al. HAEMATOLOGICA
- Geriatric assessments and frailty scores in multiple myeloma patients
- (2021) Mandy-Deborah Möller et al. CURRENT OPINION IN ONCOLOGY
- Novel immunotherapies in multiple myeloma – chances and challenges
- (2021) Leo Rasche et al. HAEMATOLOGICA
- Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors
- (2021) Laura Gengenbach et al. Cancers
- “This Graft-vs.-Host Disease Determines My Life. That's It.”—A Qualitative Analysis of the Experiences and Needs of Allogenic Hematopoietic Stem Cells Transplantation Survivors in Germany
- (2021) Mira Parisek et al. Frontiers in Public Health
- The efficacy and safety of lenalidomide in the treatment of multiple myeloma patients after allo-hematopoietic stem-cell transplantation: a systematic review and meta-analysis
- (2021) Jiansheng Zhong et al. Annals of Palliative Medicine
- Relapse after allogeneic hematopoietic cell transplantation for multiple myeloma: Survival outcomes and factors influencing them
- (2020) Saurabh Chhabra et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell
- (2020) Roni Shouval et al. BONE MARROW TRANSPLANTATION
- Graft-versus-host disease in multiple myeloma patients treated with daratumumab after allogeneic transplantation
- (2020) Liana Nikolaenko et al. Clinical Lymphoma Myeloma & Leukemia
- Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma
- (2020) Christine Eisfeld et al. ANNALS OF HEMATOLOGY
- Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma
- (2020) Sarah A. Holstein et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation
- (2020) Luciano J. Costa et al. BONE MARROW TRANSPLANTATION
- Treosulfan conditioning for allogeneic transplantation in multiple myeloma – improved overall survival in first line haematopoietic stem cell transplantation – a large retrospective study by the Chronic Malignancies Working Party of the EBMT
- (2020) Charlotte Gran et al. BRITISH JOURNAL OF HAEMATOLOGY
- Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
- (2020) Nico Gagelmann et al. BONE MARROW TRANSPLANTATION
- Allogeneic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma Treatment: Is It Still Relevant?
- (2020) Hyunkyung Park et al. Journal of Clinical Medicine
- Allogeneic hematopoietic cell transplantation for multiple myeloma: A retrospective analysis of the Polish Myeloma Group
- (2020) Aleksandra Gołos et al. Advances in Medical Sciences
- Newly diagnosed multiple myeloma patients treated with tandem auto‐allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only
- (2020) Richard LeBlanc et al. CLINICAL TRANSPLANTATION
- Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens
- (2019) Hossein Maymani et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma
- (2019) Lucia López-Corral et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma
- (2019) Jack Khouri et al. Clinical Lymphoma Myeloma & Leukemia
- High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
- (2019) Antonio Giovanni Solimando et al. Journal of Clinical Medicine
- Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
- (2019) A.R. Bryant et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Time from autologous to allogeneic hematopoietic stem cell transplantation impacts post-transplant outcomes in multiple myeloma
- (2019) Salvatore Fiorenza et al. BONE MARROW TRANSPLANTATION
- Comparison of outcomes after human leukocyte antigen-matched and haploidentical hematopoietic stem-cell transplantation for multiple myeloma
- (2019) Yao Chen et al. CHINESE MEDICAL JOURNAL
- SOHO State of the Art Updates and Next Questions: T-Cell–Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor–Modified T Cells and Bispecific T-Cell–Engaging Agents
- (2019) Deepu Madduri et al. Clinical Lymphoma Myeloma & Leukemia
- Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis
- (2019) Stefan Knop et al. LEUKEMIA
- Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial
- (2019) Sergio Giralt et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Conditioning‐based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991‐2012) on behalf of EBMT CMWP
- (2019) Patrick J. Hayden et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation
- (2019) Takashi Ikeda et al. HEMATOLOGICAL ONCOLOGY
- Teaming up for CAR-T cell therapy
- (2019) Ralph Wäsch et al. HAEMATOLOGICA
- Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft–Allograft in Multiple Myeloma
- (2018) Luisa Giaccone et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival
- (2018) Myo Htut et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study from the Japanese Society of Myeloma
- (2018) Koji Kawamura et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Posttransplant chimeric antigen receptor therapy
- (2018) Melody Smith et al. BLOOD
- Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma
- (2018) Yao Chen et al. BONE MARROW TRANSPLANTATION
- Current developments in immunotherapy in the treatment of multiple myeloma
- (2018) Martin Köhler et al. CANCER
- Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017
- (2018) Xuejiao Yin et al. Cancer Cell International
- Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)
- (2018) Alessandra Larocca et al. LEUKEMIA
- The Outcome of Haplo-Identical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report
- (2018) Firoozeh Sahebi et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life
- (2018) Christine Greil et al. HAEMATOLOGICA
- Long term follow-up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma
- (2018) Enrico Maffini et al. HAEMATOLOGICA
- Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party
- (2017) Mohamad Sobh et al. HAEMATOLOGICA
- A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
- (2017) Monika Engelhardt et al. HAEMATOLOGICA
- Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party
- (2017) Mohamad Sobh et al. HAEMATOLOGICA
- A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
- (2017) Monika Engelhardt et al. HAEMATOLOGICA
- Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features
- (2016) Leo Rasche et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
- (2016) P. Sonneveld et al. BLOOD
- Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival
- (2016) Binod Dhakal et al. Clinical Lymphoma Myeloma & Leukemia
- Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution
- (2016) Laurens E. Franssen et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party
- (2016) M Sobh et al. LEUKEMIA
- Trends in overall survival and costs of multiple myeloma, 2000–2014
- (2016) R Fonseca et al. LEUKEMIA
- Frontline therapy of multiple myeloma
- (2015) P. Moreau et al. BLOOD
- Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation
- (2015) I Ahmad et al. BONE MARROW TRANSPLANTATION
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation
- (2014) Melissa Alsina et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma
- (2014) W I Bensinger et al. BONE MARROW TRANSPLANTATION
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
- (2013) G. Gahrton et al. BLOOD
- How I assess comorbidities before hematopoietic cell transplantation
- (2013) M. L. Sorror BLOOD
- Second transplants for multiple myeloma relapsing after a previous autotransplant—reduced-intensity allogeneic vs autologous transplantation
- (2013) C O Freytes et al. BONE MARROW TRANSPLANTATION
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
- (2013) B A Walker et al. LEUKEMIA
- Bortezomib Plus Dexamethasone Followed by Escalating Donor Lymphocyte Infusions for Patients with Multiple Myeloma Relapsing or Progressing after Allogeneic Stem Cell Transplantation
- (2012) Vittorio Montefusco et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study
- (2012) H. M. Lokhorst et al. BLOOD
- Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients
- (2012) N Kröger et al. BONE MARROW TRANSPLANTATION
- Postallograft lenalidomide induces strong NK cell–mediated antimyeloma activity and risk for T cell–mediated GvHD: Results from a phase I/II dose-finding study
- (2012) Christine Wolschke et al. EXPERIMENTAL HEMATOLOGY
- Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy
- (2012) T. Coman et al. HAEMATOLOGICA
- Molecular pathogenesis of multiple myeloma and its premalignant precursor
- (2012) W. Michael Kuehl et al. JOURNAL OF CLINICAL INVESTIGATION
- Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability
- (2011) Francesca Patriarca et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma
- (2011) L. Giaccone et al. BLOOD
- Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
- (2011) E. Kneppers et al. BLOOD
- Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up
- (2011) Bo Björkstrand et al. JOURNAL OF CLINICAL ONCOLOGY
- Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
- (2011) Amrita Krishnan et al. LANCET ONCOLOGY
- Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma
- (2009) Nicolaus Kröger et al. EXPERIMENTAL HEMATOLOGY
- Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma
- (2008) P. Moreau et al. BLOOD
- A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma
- (2008) L. Rosinol et al. BLOOD
- Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting
- (2008) M. Rotta et al. BLOOD
- Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma
- (2008) H de Lavallade et al. BONE MARROW TRANSPLANTATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now